ANTX Stock Analysis: Buy, Sell, or Hold?
ANTX - AN2 Therapeutics, Inc. Common Stock
$5.20
0.22 (4.42%)
▲
5d:
+9.24%
30d:
+7.22%
90d:
+37.93%
BUY
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When ANTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ANTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ANTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ANTX is currently trading at $5.20, which is considered extended relative to its 30-day fair value range of $4.14 to $4.96.
Technical Outlook: Technically, ANTX is in a strong uptrend. Immediate support is located at $3.77, while resistance sits at $5.51. The stock is showing strong short-term momentum, up 4.4% recently.
Market Sentiment: ANTX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.00 (+73.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ANTX is in a strong uptrend. Immediate support is located at $3.77, while resistance sits at $5.51. The stock is showing strong short-term momentum, up 4.4% recently.
Market Sentiment: ANTX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.00 (+73.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$4.14 -
$4.96
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.4%)
- BULLISH: Trading 73.1% below Wall St target ($9.00)
Trading Range Analysis
30-Day Trading Range
$4.14 -
$4.96
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.77
Resistance Level
$5.51
Current Trend
Strong Uptrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.00
Wall Street Target
$9.00
(+73.1%)
Share & Embed Analysis
Last updated: June 24, 2026 9:22 PM ET
Data refreshes hourly during market hours. Next update: 10:22 PM
Data refreshes hourly during market hours. Next update: 10:22 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ANTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Sarah Joanne Williams
SELL
327 shares
2026-03-03
Joshua M Eizen
SELL
6931 shares
2026-01-06
Lucy Day
SELL
5512 shares
2026-01-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 67 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 67 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$105 | 61 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 60 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 67 BUY |
